During my visit with Dr Aparcio at MD Anderson, I asked her what trials might be appropriate for me if Lu-PSMA doesn’t lead to a durable response. She started by talking about Aggressive Variant Prostate Cancer (AVPC). Nueroendocrine Prostate Cancer is one form of AVPC , but adenocarcinoma can exhibit AVPC characteristics.
She talked about three trials for AVPC that I’ll talk about later. She said that not separating AVPC patients from patients from those without it clouds stage the trial results, and the new trials only include AVPC patients.
It took a while to sink in that the reason she was talking about AVPC, is that I’ve had AVPC since my diagnosis. In hindsight, de novo mCRPC with a PSA doubling time of three weeks is obviously an aggressive variant. I’d just never had it named that until now.
Coming to the realization was depressing for a few days, but at least now I have a framework to guide my studies. While researching tonight I came across an article linking TP53 mutation to prostate cancer.
genengnews.com/topics/cance...
My biopsy showed 10% of the cancer with the mutation. I had discounted joining a trial for this, because I wanted a treatment for 100% of the cancer. I realize that doesn’t exist. It may be that the most aggressive subtype of my cancer contains the TP53 mutation. Treating that would slow the cancer down and give me time to find treatments for the less aggressive remaining cancer.
Once again, much to learn.